Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 18/20 | 0.53 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.44 |
| ▸ | AR | P10275 | 1/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3539366 | 0.93 | HDAC1 (0.53) | HDAC1HDAC2AR | |
| SCHEMBL3532226 | 0.90 | HDAC1 (0.64) | HDAC1HDAC2HDAC8HDAC6 | |
| SCHEMBL3539983 | 0.86 | HDAC1 (0.56) | HDAC1HDAC2 | |
| SCHEMBL3538280 | 0.86 | HDAC2 (0.56) | HDAC1HDAC2HDAC8HDAC6 | |
| SCHEMBL3534436 | 0.85 | HDAC1 (0.64) | HDAC1HDAC2 | |
| SCHEMBL3542409 | 0.83 | HDAC1 (0.64) | HDAC1HDAC2HDAC8HDAC6 | |
| SCHEMBL3534349 | 0.80 | HDAC1 (0.56) | HDAC1HDAC2 | |
| SCHEMBL3536652 | 0.80 | HDAC1 (0.58) | HDAC1HDAC2 | |
| SCHEMBL3542874 | 0.80 | HDAC1 (0.56) | HDAC1HDAC2HDAC8HDAC6 | |
| SCHEMBL3537402 | 0.79 | HDAC1 (0.66) | HDAC1ARHDAC8HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7642275-B2 | Histone deacetylase inhibitors | TAKEDA SAN DIEGO, INC. (US) | 2010-01-05 | — | — | US | claimed |
| EP-1824831-A2 | HISTONE DEACETYLASE INHIBITORS | Takeda San Diego, Inc. (US) | 2007-08-29 | — | — | EP | claimed |
| US-20060205941-A1 | Histone deacetylase inhibitors | TAKEDA SAN DIEGO, INC. | 2006-09-14 | — | — | US | claimed |
| WO-2006066133-A2 | HISTONE DEACETYLASE INHIBITORS | TAKEDA SAN DIEGO, INC. (US) | 2006-06-22 | — | — | WO | claimed |
| US-7642275-B2 | Histone deacetylase inhibitors | TAKEDA SAN DIEGO, INC. (US) | 2010-01-05 | — | — | US | disclosed |
| US-7642275-B2 | Histone deacetylase inhibitors | TAKEDA SAN DIEGO, INC. (US) | 2010-01-05 | — | — | US | disclosed |
| US-20060205941-A1 | Histone deacetylase inhibitors | TAKEDA SAN DIEGO, INC. | 2006-09-14 | — | — | US | disclosed |
| WO-2006066133-A2 | HISTONE DEACETYLASE INHIBITORS | TAKEDA SAN DIEGO, INC. (US) | 2006-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060205941-A1 | Histone deacetylase inhibitors | HDAC1, HDAC3, HDAC5 | HDAC1 1/4885HDAC2 4/4885AR 897/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.